See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Natural Disasters
Social Media
Artificial Intelligence
Tariffs
Donald Trump
Stock Markets
Baseball
European Union
Soccer
Vladimir Putin
Tesla
Published • loading... • Updated

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Summary by Hastings Tribune
THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and…

7 Articles

All
Left
Center
3
Right
1
Investor's Business DailyInvestor's Business Daily
Right

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1

Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment. The post Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 appeared first on Investor's Business Daily.

Read Full Article
BenzingaBenzinga
Center

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Lexicon Pharmaceuticals (NASDAQ:LXRX), Novo Nordisk (NYSE:NVO)

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:NVO) on Friday for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture, and commercialize L…

·New York, United States
Read Full Article
Hastings TribuneHastings Tribune
Center

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and…

Read Full Article
biopharmadive.combiopharmadive.com
Center

Novo gains Lexicon obesity drug; CRISPR COO to step down

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off 57% of its workforce and Bicycle Therapeutics shook up its leadership team.

Read Full Article
MedCity NewsMedCity News

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP

Novo Nordisk gets global rights to Lexicon Pharmaceuticals’ LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisk’s Wegovy. The post Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s appeared first on MedC…

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Pharmaceutical Technology

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy LX9851.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)

Similar News Topics

Obesity

Obesity

Stock Markets

Stock Markets

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal